Schoenfeld JD, Giobbie-Hurder A, Ranasinghe S, Kao KZ, et al. Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial. Lancet Oncol 2022 Jan 13. pii: S1470-2045(21)00658.
PMID: 35033226